{"id":"vemurafenib-and-cobimetinib","safety":{"commonSideEffects":[{"effect":"Diarrhoea","drugRate":"34.6%","placeboRate":"","totalAtRisk":1075,"totalAffected":372,"trialsReporting":6},{"effect":"Nausea","drugRate":"26.2%","placeboRate":"","totalAtRisk":1075,"totalAffected":282,"trialsReporting":6},{"effect":"Fatigue","drugRate":"24.0%","placeboRate":"","totalAtRisk":1075,"totalAffected":258,"trialsReporting":6},{"effect":"Anaemia","drugRate":"19.7%","placeboRate":"","totalAtRisk":1075,"totalAffected":212,"trialsReporting":6},{"effect":"Rash","drugRate":"16.2%","placeboRate":"","totalAtRisk":1075,"totalAffected":174,"trialsReporting":6},{"effect":"Arthralgia","drugRate":"15.5%","placeboRate":"","totalAtRisk":1075,"totalAffected":167,"trialsReporting":6},{"effect":"Decreased appetite","drugRate":"14.7%","placeboRate":"","totalAtRisk":1075,"totalAffected":158,"trialsReporting":6},{"effect":"Vomiting","drugRate":"13.8%","placeboRate":"","totalAtRisk":1075,"totalAffected":148,"trialsReporting":6},{"effect":"Pyrexia","drugRate":"13.4%","placeboRate":"","totalAtRisk":1075,"totalAffected":144,"trialsReporting":6},{"effect":"Constipation","drugRate":"11.4%","placeboRate":"","totalAtRisk":1075,"totalAffected":123,"trialsReporting":6},{"effect":"Abdominal pain","drugRate":"11.3%","placeboRate":"","totalAtRisk":1075,"totalAffected":121,"trialsReporting":6},{"effect":"Pruritus","drugRate":"9.9%","placeboRate":"","totalAtRisk":1075,"totalAffected":106,"trialsReporting":6},{"effect":"Asthenia","drugRate":"13.9%","placeboRate":"","totalAtRisk":718,"totalAffected":100,"trialsReporting":5},{"effect":"Cough","drugRate":"8.2%","placeboRate":"","totalAtRisk":1075,"totalAffected":88,"trialsReporting":6},{"effect":"Neutropenia","drugRate":"18.0%","placeboRate":"","totalAtRisk":471,"totalAffected":85,"trialsReporting":3},{"effect":"Back pain","drugRate":"7.9%","placeboRate":"","totalAtRisk":1075,"totalAffected":85,"trialsReporting":6},{"effect":"Dyspnoea","drugRate":"7.8%","placeboRate":"","totalAtRisk":1075,"totalAffected":84,"trialsReporting":6},{"effect":"Oedema peripheral","drugRate":"7.7%","placeboRate":"","totalAtRisk":1075,"totalAffected":83,"trialsReporting":6},{"effect":"Headache","drugRate":"7.3%","placeboRate":"","totalAtRisk":1075,"totalAffected":79,"trialsReporting":6},{"effect":"Aspartate aminotransferase increased","drugRate":"6.9%","placeboRate":"","totalAtRisk":1075,"totalAffected":74,"trialsReporting":6},{"effect":"Myalgia","drugRate":"6.6%","placeboRate":"","totalAtRisk":1075,"totalAffected":71,"trialsReporting":6},{"effect":"Blood alkaline phosphatase increased","drugRate":"6.7%","placeboRate":"","totalAtRisk":1009,"totalAffected":68,"trialsReporting":5},{"effect":"Alanine aminotransferase increased","drugRate":"6.2%","placeboRate":"","totalAtRisk":1075,"totalAffected":67,"trialsReporting":6},{"effect":"Urinary tract infection","drugRate":"6.1%","placeboRate":"","totalAtRisk":1075,"totalAffected":66,"trialsReporting":6},{"effect":"Weight decreased","drugRate":"6.1%","placeboRate":"","totalAtRisk":1060,"totalAffected":65,"trialsReporting":5},{"effect":"Insomnia","drugRate":"6.0%","placeboRate":"","totalAtRisk":1075,"totalAffected":65,"trialsReporting":6},{"effect":"Chills","drugRate":"9.7%","placeboRate":"","totalAtRisk":670,"totalAffected":65,"trialsReporting":4},{"effect":"Blood creatinine increased","drugRate":"5.8%","placeboRate":"","totalAtRisk":1075,"totalAffected":62,"trialsReporting":6},{"effect":"Blood creatine phosphokinase increased","drugRate":"14.8%","placeboRate":"","totalAtRisk":406,"totalAffected":60,"trialsReporting":4},{"effect":"Infusion related reaction","drugRate":"8.2%","placeboRate":"","totalAtRisk":697,"totalAffected":57,"trialsReporting":4},{"effect":"Hypertension","drugRate":"7.9%","placeboRate":"","totalAtRisk":718,"totalAffected":57,"trialsReporting":5},{"effect":"Thrombocytopenia","drugRate":"11.5%","placeboRate":"","totalAtRisk":486,"totalAffected":56,"trialsReporting":4},{"effect":"Dry skin","drugRate":"7.2%","placeboRate":"","totalAtRisk":748,"totalAffected":54,"trialsReporting":4},{"effect":"Hypokalaemia","drugRate":"4.8%","placeboRate":"","totalAtRisk":1075,"totalAffected":52,"trialsReporting":6},{"effect":"Dizziness","drugRate":"4.8%","placeboRate":"","totalAtRisk":1075,"totalAffected":52,"trialsReporting":6},{"effect":"Neuropathy peripheral","drugRate":"12.1%","placeboRate":"","totalAtRisk":405,"totalAffected":49,"trialsReporting":2},{"effect":"Rash maculo-papular","drugRate":"6.4%","placeboRate":"","totalAtRisk":763,"totalAffected":49,"trialsReporting":5},{"effect":"Peripheral sensory neuropathy","drugRate":"11.6%","placeboRate":"","totalAtRisk":405,"totalAffected":47,"trialsReporting":2},{"effect":"Neutrophil count decreased","drugRate":"11.4%","placeboRate":"","totalAtRisk":405,"totalAffected":46,"trialsReporting":2},{"effect":"Platelet count decreased","drugRate":"10.4%","placeboRate":"","totalAtRisk":405,"totalAffected":42,"trialsReporting":2},{"effect":"Pain in extremity","drugRate":"5.8%","placeboRate":"","totalAtRisk":718,"totalAffected":42,"trialsReporting":5},{"effect":"Alopecia","drugRate":"5.7%","placeboRate":"","totalAtRisk":718,"totalAffected":41,"trialsReporting":5},{"effect":"Abdominal pain upper","drugRate":"5.4%","placeboRate":"","totalAtRisk":718,"totalAffected":39,"trialsReporting":5},{"effect":"Photosensitivity reaction","drugRate":"9.4%","placeboRate":"","totalAtRisk":406,"totalAffected":38,"trialsReporting":4},{"effect":"Stomatitis","drugRate":"8.9%","placeboRate":"","totalAtRisk":406,"totalAffected":36,"trialsReporting":4},{"effect":"Blood bilirubin increased","drugRate":"4.7%","placeboRate":"","totalAtRisk":763,"totalAffected":36,"trialsReporting":5},{"effect":"Dermatitis acneiform","drugRate":"8.4%","placeboRate":"","totalAtRisk":406,"totalAffected":34,"trialsReporting":4},{"effect":"Hypomagnesaemia","drugRate":"7.2%","placeboRate":"","totalAtRisk":405,"totalAffected":29,"trialsReporting":2},{"effect":"Muscle spasms","drugRate":"4.3%","placeboRate":"","totalAtRisk":682,"totalAffected":29,"trialsReporting":3},{"effect":"Sunburn","drugRate":"7.4%","placeboRate":"","totalAtRisk":391,"totalAffected":29,"trialsReporting":3}]},"_chembl":{"chemblId":"CHEMBL4538425","moleculeType":"Unknown","molecularWeight":"531.32"},"_fixedAt":"2026-03-30T11:30:39.268063","allNames":"vemurafenib and cobimetinib","_dailymed":null,"mechanism":{"target":"BRAF, MEK","drugClass":"BRAF inhibitor, MEK inhibitor","explanation":"Vemurafenib targets the BRAF protein, which is often mutated in melanoma, while cobimetinib blocks MEK, another key player in the same pathway. Together, they effectively stop cancer cells from growing and spreading.","oneSentence":"Vemurafenib and cobimetinib inhibit the BRAF and MEK enzymes, respectively, disrupting the MAPK signaling pathway to halt tumor growth in melanoma."},"_scrapedAt":"2026-03-28T01:49:12.119Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:45:57.782346+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_fixedFields":["modality→Small Molecule"],"trialDetails":[{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":720},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":4200},{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT04302025","phase":"PHASE2","title":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2020-11-06","conditions":"Non-small Cell Lung Cancer","enrollment":99},{"nctId":"NCT07448480","phase":"","title":"Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2026-02-01","conditions":"Recurrent Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma","enrollment":1000},{"nctId":"NCT06440850","phase":"PHASE2","title":"Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-07-15","conditions":"Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma","enrollment":21},{"nctId":"NCT03768063","phase":"PHASE3","title":"A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-02-28","conditions":"Cancer","enrollment":1000},{"nctId":"NCT03181100","phase":"PHASE2","title":"Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-07-27","conditions":"Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8","enrollment":50},{"nctId":"NCT03554083","phase":"PHASE2","title":"Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-10-05","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","enrollment":59},{"nctId":"NCT05768178","phase":"PHASE2, PHASE3","title":"DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.","status":"RECRUITING","sponsor":"Cancer Research UK","startDate":"2023-03-01","conditions":"Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary","enrollment":30},{"nctId":"NCT05722886","phase":"PHASE2, PHASE3","title":"DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol","status":"RECRUITING","sponsor":"Cancer Research UK","startDate":"2023-03-01","conditions":"Haematological Malignancy, Solid Tumour","enrollment":825},{"nctId":"NCT03498521","phase":"PHASE2","title":"A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-07-10","conditions":"Cancer of Unknown Primary Site","enrollment":529},{"nctId":"NCT04341181","phase":"PHASE2","title":"ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling","status":"RECRUITING","sponsor":"Ulrik Lassen","startDate":"2020-08-24","conditions":"Cancer, Tumors, Neoplasms","enrollment":300},{"nctId":"NCT02908672","phase":"PHASE3","title":"A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-01-13","conditions":"Melanoma","enrollment":514},{"nctId":"NCT02902029","phase":"PHASE2","title":"Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2016-11","conditions":"Malignant Melanoma","enrollment":186},{"nctId":"NCT04722575","phase":"PHASE2","title":"Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Melanoma Onlus","startDate":"2020-10-12","conditions":"Melanoma","enrollment":95},{"nctId":"NCT03224767","phase":"PHASE2","title":"Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2018-01-05","conditions":"BRAF V600E Mutation Present, Papillary Craniopharyngioma","enrollment":24},{"nctId":"NCT03026517","phase":"PHASE1","title":"Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-01","conditions":"Melanoma","enrollment":18},{"nctId":"NCT04551521","phase":"PHASE2","title":"CRAFT: The NCT-PMO-1602 Phase II Trial","status":"COMPLETED","sponsor":"German Cancer Research Center","startDate":"2021-10-13","conditions":"Metastatic or Locally Advanced Malignancies","enrollment":72},{"nctId":"NCT02091141","phase":"PHASE2","title":"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2014-04-14","conditions":"Neoplasms, Solid Tumors, Biliary Cancer","enrollment":673},{"nctId":"NCT02291289","phase":"PHASE2","title":"A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-04-17","conditions":"Colorectal Cancer","enrollment":1044},{"nctId":"NCT03625141","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-12-13","conditions":"Metastatic Melanoma","enrollment":80},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT04817956","phase":"PHASE2","title":"Improving Public Cancer Care by Implementing Precision Medicine in Norway","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2021-04-01","conditions":"Cancer Metastatic","enrollment":3000},{"nctId":"NCT02925234","phase":"PHASE2","title":"The Drug Rediscovery Protocol (DRUP Trial)","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2016-08","conditions":"Cancer, Tumors, Neoplasm","enrollment":1550},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":""},{"nctId":"NCT02382549","phase":"EARLY_PHASE1","title":"A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib","status":"TERMINATED","sponsor":"Craig L Slingluff, Jr","startDate":"2016-04","conditions":"Melanoma","enrollment":8},{"nctId":"NCT04591431","phase":"PHASE2","title":"The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy","status":"UNKNOWN","sponsor":"Fondazione per la Medicina Personalizzata","startDate":"2020-10-07","conditions":"Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer","enrollment":400},{"nctId":"NCT04801966","phase":"NA","title":"Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study","status":"TERMINATED","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2021-09-23","conditions":"Cancer","enrollment":3},{"nctId":"NCT05611229","phase":"","title":"Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-16","conditions":"Metastatic Melanoma","enrollment":1975},{"nctId":"NCT02414750","phase":"PHASE2","title":"Vemurafenib Plus Cobimetinib in Metastatic Melanoma","status":"TERMINATED","sponsor":"Netherlands Working Group on Immunotherapy of Oncology","startDate":"2014-12","conditions":"Metastatic Melanoma","enrollment":78},{"nctId":"NCT02036086","phase":"PHASE2","title":"Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases","status":"UNKNOWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2015-08","conditions":"Melanoma","enrollment":24},{"nctId":"NCT05402059","phase":"","title":"Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice","status":"UNKNOWN","sponsor":"MelanomaPRO, Russia","startDate":"2022-03-02","conditions":"Melanoma, Melanoma (Skin), Melanoma, Uveal","enrollment":1570},{"nctId":"NCT01959633","phase":"PHASE1, PHASE2","title":"Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation","status":"COMPLETED","sponsor":"Fondazione Melanoma Onlus","startDate":"2014-04-03","conditions":"Melanoma","enrollment":11},{"nctId":"NCT02818023","phase":"PHASE1","title":"Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma","status":"TERMINATED","sponsor":"Yana Najjar","startDate":"2016-07-13","conditions":"Melanoma","enrollment":9},{"nctId":"NCT03514901","phase":"PHASE2","title":"To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.","status":"UNKNOWN","sponsor":"Intergruppo Melanoma Italiano","startDate":"2018-06-18","conditions":"Melanoma Metastatic, BRAF V600 Mutation","enrollment":120},{"nctId":"NCT02303951","phase":"PHASE2","title":"Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC","status":"TERMINATED","sponsor":"University Hospital Tuebingen","startDate":"2015-01-22","conditions":"Malignant Melanoma","enrollment":47},{"nctId":"NCT01656642","phase":"PHASE1","title":"A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-08-13","conditions":"Malignant Melanoma","enrollment":67},{"nctId":"NCT02968303","phase":"PHASE2","title":"Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2017-01-27","conditions":"Melanoma, Malignant, of Soft Parts","enrollment":200},{"nctId":"NCT02583516","phase":"PHASE2","title":"Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma","status":"COMPLETED","sponsor":"Grupo Español Multidisciplinar de Melanoma","startDate":"2015-06-30","conditions":"Melanoma","enrollment":70},{"nctId":"NCT02537600","phase":"PHASE2","title":"Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis","status":"COMPLETED","sponsor":"Center Eugene Marquis","startDate":"2015-12","conditions":"Malignant Melanoma","enrollment":43},{"nctId":"NCT03108209","phase":"NA","title":"Prevention of Phototoxicities in Patients Undergoing Vemurafenib Treatment","status":"COMPLETED","sponsor":"Michele Sayag","startDate":"2016-07","conditions":"Phototoxicity","enrollment":30},{"nctId":"NCT01271803","phase":"PHASE1","title":"A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-02-17","conditions":"Malignant Melanoma","enrollment":131},{"nctId":"NCT01813214","phase":"PHASE2","title":"The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2013-03","conditions":"Melanoma","enrollment":5},{"nctId":"NCT03139513","phase":"","title":"A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-10-27","conditions":"Melanoma","enrollment":200},{"nctId":"NCT01876641","phase":"PHASE1","title":"Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib","status":"TERMINATED","sponsor":"Mohammed M Milhem","startDate":"2013-10","conditions":"Metastatic Melanoma, Melanoma, BRAF-mutated Metastatic Melanoma","enrollment":18},{"nctId":"NCT03005639","phase":"PHASE2","title":"ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma","status":"WITHDRAWN","sponsor":"Inova Health Care Services","startDate":"2017-06-01","conditions":"Stage IIIB-C Melanoma","enrollment":""},{"nctId":"NCT01495988","phase":"PHASE2","title":"Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma","status":"TERMINATED","sponsor":"Melanoma Research Foundation Breakthrough Consortium","startDate":"2013-08","conditions":"Melanoma, Metastatic Melanoma","enrollment":10},{"nctId":"NCT02230306","phase":"PHASE2","title":"Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases","status":"TERMINATED","sponsor":"Melissa Burgess, MD","startDate":"2015-02","conditions":"Active Melanoma Brain Metastases","enrollment":5},{"nctId":"NCT01843738","phase":"PHASE1","title":"Radiation Use During Vemurafenib Treatment","status":"WITHDRAWN","sponsor":"University of Utah","startDate":"2017-06","conditions":"BRAFV600 Mutation, Stage IV Melanoma","enrollment":""},{"nctId":"NCT02427893","phase":"PHASE3","title":"Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-08","conditions":"Melanoma","enrollment":""},{"nctId":"NCT01974258","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2014-02","conditions":"Neoplasms","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Vemurafenib and Cobimetinib","genericName":"vemurafenib-and-cobimetinib","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":7,"trialStats":{"total":14,"withResults":6},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:45:57.782346+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}